Chemiluminescent Immunoassay (CLIA) Kits

Achieve unparalleled sensitivity in biomarker quantification with St John's Laboratory's Chemiluminescent Immunoassay (CLIA) kits. Harnessing the power of light-emitting enzymatic reactions, our CLIA kits deliver exceptional detection limits, broad dynamic ranges, and minimal background - ideal for measuring low-abundance cytokines, hormones, and disease markers in serum, plasma, and other complex biological samples.

Why Choose CLIA Over Conventional ELISA?

Superior Sensitivity

Chemiluminescence detection offers 10–100× greater sensitivity than chromogenic ELISA, enabling quantification of trace analytes in challenging samples.

Wider Dynamic Range

Accurate measurement across 3–5 orders of magnitude, accommodating both low and high analyte concentrations in a single assay.

Lower Background Signal

Light emission from enzymatic reactions produces minimal noise compared to absorbance-based methods, improving signal-to-noise ratios.

Versatile Applications

Validated for proteins, antibodies, bacterial toxins, and other antigens across human and model species (mouse, rat, pig).

CLIA Technology Assay Workflow Browse by Species Research Applications
CLIA Technology

CLIA Technology: Light-Based Detection for Maximum Sensitivity

Chemiluminescent immunoassays represent a significant advancement over traditional colorimetric methods. Instead of measuring light absorption (as in TMB- or ABTS-based ELISA), CLIA quantifies light emission from enzymatic reactions involving substrates like luminol. This fundamental difference unlocks:

Conventional ELISA (Colorimetric)

  • • Absorbance-based detection
  • • Limited sensitivity (pg–ng/mL)
  • • Narrow dynamic range (1–2 logs)
  • • Higher background interference

CLIA (Chemiluminescent)

  • • Light emission detection
  • • Ultra-high sensitivity (fg–pg/mL)
  • • Broad dynamic range (3–5 logs)
  • • Minimal background noise

The result: reliable quantification of low-abundance targets previously undetectable by standard immunoassays.

Sandwich CLIA Workflow

Our CLIA kits employ a validated sandwich immunoassay format optimised for specificity and reproducibility:

Browse All CLIA Kits

Step-by-Step Protocol

  1. Capture: Microplate wells pre-coated with analyte-specific capture antibody bind target molecules from samples or standards.
  2. Detection: Biotinylated detection antibody recognises a distinct epitope, forming a sandwich complex.
  3. Signal Amplification: Avidin-HRP conjugate binds biotin, positioning horseradish peroxidase at the detection site.
  4. Washing: Unbound components removed to eliminate background signal.
  5. Substrate Addition: Chemiluminescent substrate (luminol + enhancers) reacts with HRP, generating light.
  6. Quantification: Luminometer measures Relative Light Units (RLU). Analyte concentration determined via standard curve.

RLU is directly proportional to analyte concentration - higher RLU indicates higher target levels.

CLIA Kits by Species Reactivity

Select validated kits for your model organism or clinical samples:

Human

347 Kits

Mouse

135 Kits

Rat

114 Kits

Featured Research Applications

Oncology & Metabolic Disease

NAMPT/Visfatin in Cancer Metabolism

Nicotinamide phosphoribosyltransferase (NAMPT), also known as visfatin, is the rate-limiting enzyme in the NAD⁺ salvage pathway - critical for cellular energy homeostasis and DNA repair. NAMPT overexpression correlates with poor prognosis in multiple cancers, making it a promising therapeutic target.

The Human NAMPT/Visfatin CLIA Kit (STJC0000780) enables sensitive measurement of circulating NAMPT in serum, plasma, and biological fluids - supporting research into metabolic reprogramming, obesity-related inflammation, and cancer progression.

Neurology & Brain Injury

S100B as a Neural Biomarker

S100B, a calcium- and zinc-binding protein predominantly expressed in glial cells, serves as a biomarker for neural injury and neuroinflammation. Following traumatic brain injury or stroke, damaged glial cells release S100B into circulation. Elevated serum S100B correlates with injury severity and is implicated in Alzheimer's disease and Parkinson's disease pathology.

The Human S100B CLIA Kit (STJC0000599) offers high specificity with no cross-reactivity to analogues, enabling precise quantification for neurology research and clinical biomarker studies.

Featured CLIA Kits

Target Product SKU Species Research Area
NAMPT (Visfatin) Human NAMPT CLIA Kit STJC0000780 Human Cancer metabolism, obesity
S100B Human S100B CLIA Kit STJC0000599 Human Neurology, brain injury

Key Advantages of Chemiluminescent Detection

Trace Analyte Detection

Measure femtogram to picogram concentrations - essential for cytokines, hormones, and rare biomarkers.

Reduced Sample Volume

High sensitivity allows quantification from smaller sample inputs, preserving precious clinical or experimental material.

Complex Sample Compatibility

Validated for serum, plasma, cell culture supernatants, and tissue lysates without extensive purification.

Reproducible Results

Low inter- and intra-assay variability ensures reliable data across experiments and batches.

Need Help Selecting a CLIA Kit?

Our technical team can recommend the optimal kit for your target analyte, sample type, and sensitivity requirements.

Contact Our CLIA Specialists

For Research Use Only - All products are intended for research purposes and are not for use in diagnostic procedures

!